1. Centers for Disease Control and Prevention. Cytomegalovirus (CMV) and congenital CMV infection—for healthcare professionals: clinical overview. 2016. https://www.cdc.gov/. Accessed 1 Dec 2017.
2. Centers for Disease Control and Prevention. Cytomegalovirus (CMV) and congenital CMV infection: about CMV. 2016. https://www.cdc.gov/. Accessed 1 Dec 2017.
3. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25(1):151–69.
4. Maffini E, Giaccone L, Festuccia M, et al. Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol. 2016;9(6):585–96.
5. Merck. Merck receives FDA approval of PREVYMIS™ (letermovir) for prevention of cytomegalovirus (CMV) infection and disease in adult allogeneic stem cell transplant patients [media release]. 9 Nov 2017. http://www.mrknewsroom.com.